Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · 4

BridgeBio Oncology Therapeutics, Inc.

BBOTNASDAQEQUITYCurrent

SEC Filing

Filed Sep 14, 2026Accepted Sep 14, 2026, 4:24 PM EDTCIK 1869105Accession 0001193125-26-390624
Share

Company context

Helix Acquisition Corp. II (Nasdaq: HLXB) is a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. Helix Acquisition Corp. II raised $184 million in its initial public offering on February 9, 2024. Helix is sponsored by affiliates of Cormorant Asset Management and is headquartered in Boston, Massachusetts.

Current securities

Recent company filings

  1. EFFECT filingSep 10, 2026
  2. EFFECT filingSep 8, 2026
  3. Other EventsSep 8, 2026
  4. S-3 filingSep 1, 2026
  5. POS AM filingSep 1, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗